Angiex Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$31M
- Investors
-
20
Angiex General Information
Description
Developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis. The company's antibody-drug conjugate therapy for solid cancers enables rapid development of nuclear-delivered antibody-drug conjugates that deliver conjugated payloads directly to the nucleus in tumor cells and to the activated endothelium of cancers and inflamed vessels, enabling healthcare providers to cure human cancers such as pancreatic, lung, and liver cancers and glioblastoma multiforme.
Contact Information
Website
www.angiex.comCorporate Office
- 150 Cambridge Park Drive
- 5th floor
- Cambridge, MA 02140
- United States
Corporate Office
- 150 Cambridge Park Drive
- 5th floor
- Cambridge, MA 02140
- United States
Angiex Timeline
Angiex Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 17-Nov-2025 | $31M | Completed | Clinical Trials - Phase 1 | ||
| 7. Later Stage VC | 30-Sep-2024 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series B) | 30-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Secondary Transaction - Private | 03-Nov-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A1) | 13-Dec-2018 | Completed | Startup | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Early Stage VC (Series A) | 28-Jul-2017 | $3.7M | $3.7M | Completed | Startup | |
| 1. Accelerator/Incubator | 02-Nov-2016 | Completed | Startup |
Angiex Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-1 | 310,959 | $0.000100 | 8% | $18.59 | $18.59 | 1x | $18.59 | 9.48% |
| Series A | 629,759 | $0.000100 | 8% | $9.29 | $9.29 | 1x | $9.29 | 19.21% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Angiex Comparisons
Industry
Financing
Details
Angiex Competitors (12)
One of Angiex’s 12 competitors is Sorrento Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Seagen | Formerly VC-backed | Bothell, WA | ||||
| Klus Pharma | Corporate Backed or Acquired | Princeton, NJ | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland |
Angiex Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Angiex Patents
Angiex Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4536290-A1 | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same | Pending | 08-Jun-2022 | ||
| US-20250152730-A1 | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same | Pending | 08-Jun-2022 | ||
| WO-2023239803-A1 | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same | Inactive | 08-Jun-2022 | ||
| US-20240342302-A1 | Degrader-antibody conjugates and methods of using same | Pending | 30-Sep-2021 | ||
| WO-2023056069-A1 | Degrader-antibody conjugates and methods of using same | Inactive | 30-Sep-2021 | A61K47/6849 |
Angiex Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Angiex Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Opus8 | PE/Buyout | Minority | ||
| Paulson Investment Company | Investment Bank | Minority | ||
| Angel (individual) | Minority | |||
| K5 Global | Venture Capital | Minority | ||
| Nudel Holdings | Venture Capital | Minority |
Angiex FAQs
-
When was Angiex founded?
Angiex was founded in 2015.
-
Where is Angiex headquartered?
Angiex is headquartered in Cambridge, MA.
-
What is the size of Angiex?
Angiex has 5 total employees.
-
What industry is Angiex in?
Angiex’s primary industry is Drug Discovery.
-
Is Angiex a private or public company?
Angiex is a Private company.
-
What is Angiex’s current revenue?
The current revenue for Angiex is .
-
How much funding has Angiex raised over time?
Angiex has raised $98.7M.
-
Who are Angiex’s investors?
Opus8, Paulson Investment Company, , K5 Global, and Nudel Holdings are 5 of 20 investors who have invested in Angiex.
-
Who are Angiex’s competitors?
Sorrento Therapeutics, Seagen, Klus Pharma, Sutro Biopharma, and ADC Therapeutics are some of the 12 competitors of Angiex.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
